Immunotherapy

The Global Allergy and Asthma Excellence Network, or GA2LEN, will host its biannual global meeting from Sept. 5 to 7.

Healio has compiled August’s most-read news in asthma and allergy.

A novel therapeutic approach stimulated new and existing T-cell responses among patients with melanoma or non-small cell lung cancer, according to results of a phase 1 trial.

SAN ANTONIO — Tricia Sowers, PhD, introduced attendees to allergenic trees along the River Walk and discussed how immunotherapy can address them at the 16th Annual Allergy, Asthma & Immunology CME Conference.

During a shareholder presentation in front of more than 500 physicians in April, Debra A. Patt, MD, PhD, MBA, FASCO, asked how many in attendance used large language models like ChatGPT and Claude.

Oregon Health & Science University has implemented a “symptom science” clinical research program designed to mitigate toxicities and improve quality of life for people with cancer.

The ADAPT OIT program builds peanut tolerance in babies with daily dosing of peanut powder administered by caregivers at home, according to a National Allergy Centre of Excellence and Murdoch Children’s Research Institute press release.

DBV Technologies recently provided updates on its Viaskin Peanut Program for children and toddlers, announcing recruitment for the VITESSE study and progress in the COMFORT Toddlers supplemental safety study.

The addition of tafasitamab-cxix to lenalidomide and rituximab improved outcomes for patients with relapsed or refractory follicular lymphoma, according to the agent’s manufacturer.

Neoadjuvant immunotherapy may allow more people with hepatocellular carcinoma to undergo surgical resection, according to retrospective study results.